Wegovy 7.2mg: the facts behind the higher dose

The biggest misconception: 7.2mg is not a shortcut to faster results

Much of the coverage around the 7.2mg approval framed it as a leap, a new, more powerful injection that people could simply switch to. That is not quite right. The 7.2mg dose is the maintenance ceiling. Getting there still means starting at 0.25mg semaglutide and moving up through the prescriber-supervised titration schedule roughly every four weeks. Skipping steps is not how the medicine works; the slower ramp exists to give your body time to adapt and to keep side effects manageable.

The pen itself is genuinely new, the dedicated 7.2mg single-dose device approved in April 2026 is a different format from the earlier arrangement of three 2.4mg pens. It has an auto-dosing mechanism and a covered needle that locks after the injection is given. When it arrives from a Wegovy-dispensing pharmacy, it comes in plain, unbranded packaging via tracked delivery, a DPD notification on your phone tells you when to expect it. But the device change does not alter the titration requirement; it simply makes the maintenance dose easier to administer.

People often arrive at consultations having read that 7.2mg is "basically the same as tirzepatide now." The evidence is more nuanced. Trials at 7.2mg reported approximately 20.7% average weight loss over 72 weeks, which does narrow the gap, but the two medicines work through different pathways and suitability is always an individual clinical call. You can read a detailed breakdown of the evidence on our semaglutide 7.2mg overview.

Who the 7.2mg licence actually covers, and one firm boundary

The MHRA's approval for the 7.2mg pen is specific: adults with a BMI of 30 or above, using the medicine alongside a reduced-calorie diet and increased physical activity. That is the licensed population. The 27–29.9 BMI band with a weight-related condition (which qualifies for the lower Wegovy doses) does not extend to 7.2mg under the current approval. That boundary matters, and a prescriber will apply it.

Titration to 7.2mg is also at the prescriber's discretion. Someone who has not tolerated the 2.4mg maintenance dose well is unlikely to be taken to a higher level without careful clinical review. If you want to understand how the full Wegovy dose schedule works, that page covers each step from 0.25mg upward.

People already established on 2.4mg weekly who want to discuss 7.2mg should raise it at their next clinical review, not change anything unilaterally. The prescriber will weigh your current response, tolerability history and overall picture. A BMI figure alone does not determine the outcome of that conversation.

Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, a prescriber will take this into account during assessment.

What the trial evidence shows, and what it does not

The 20.7% average weight-loss figure at 72 weeks is a meaningful result. For context, the STEP 1 trial of semaglutide 2.4mg, published in the New England Journal of Medicine, showed approximately 15% average reduction over 68 weeks. The higher dose does appear to produce meaningfully greater loss for many participants.

Two caveats are worth stating plainly. First, averages hide a wide spread, some people lose considerably more, some considerably less, and clinical trials include intensive lifestyle support that does not always mirror everyday life. Second, the 7.2mg pen was approved in the UK in April 2026; the body of real-world evidence is still building. The timeline of UK approval and what it means in practice is covered separately.

Side effects at 7.2mg follow the same gastrointestinal pattern seen across the semaglutide programme (nausea, loose stools, constipation and indigestion are the most commonly reported) though incidence and severity can be higher at higher doses. Our 7.2mg side effects page goes into detail, including when symptoms warrant medical attention. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk lets anyone report a suspected side effect directly to the regulator.

NHS access versus the private route

The NHS currently provides Wegovy through specialist weight management services under NICE guidance (TA875), with waiting lists that can run to months or longer in many areas. The 7.2mg dose, having received MHRA approval only in April 2026, sits within that specialist pathway, but access is far from immediate or universal. The availability timeline sets out what is known about rollout so far.

For those who want access without the wait, a private prescription through a regulated online pharmacy is the legal alternative. Any pharmacy offering Wegovy should be verifiable on the GPhC register; a GPhC registration number lets you confirm the premises are licensed to dispense. If you are weighing up the cost of private treatment, our treatment and pricing page sets out what is included at nume (consultation, prescription, delivery and ongoing clinical support) with no subscription and no hidden charges.

A consultation with one of our prescribers is the right starting point if you want to know whether 7.2mg is a realistic option for you. Speak to our prescribers through the link above, and a GPhC-registered Independent Prescriber will review your case the same day.